All publications

Export 21 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin CA, Phillips AN, Allen E., Pillay D.  2008.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.
Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Predictors of death and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Green H, Pozniak A, Porter K, UK HIV Drug Resistance Database.  2003.  Temporal patterns in the rate of transmitted resistance in the UK. 9th European AIDS Conference, 25-29 October 2003.
Green H, Tilston P, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2007.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the UK. 2nd International Workshop on HIV Transmission, 26-28 August 2007.
Green H, Tilston P, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2007.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the UK. 13th Annual Conference of the British HIV Association, 25-28 April 2007.
Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT.  2008.  The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.
Gifford RJM, de Oliveira T, Rambaut A, Myers R.E, Gale C.V, Dunn DT, Shafer R., Vandamme A.M, Kellam P, Pillay D.  2006.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS. 20:1521-9.
Gifford RJM, Pillay D, UK HIV Drug Resistance Database.  2005.  Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Gifford RJM, de Oliveira T, Rambaut A, Pybus OG, Dunn DT, Vandamme A.M, Kellam P, Pillay D, UK HIV Drug Resistance Database.  2008.  Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Gifford RJM, Kellam P, Dunn DT, Pillay D, UK HIV Drug Resistance Database.  2006.  The impact of structural and functional constraints acting at the nucleic acid level on the evolution of drug resistance in HIV-1. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Geretti AM, Sabin CA, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2006.  The H208Y mutation in reverse transcriptase is significantly associated with NRTI exposure, M184V and TAM mutation pathways. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
Geretti AM, Harrison LJ, Green H, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Effect of HIV-1 subtype on virological and immunological response to first-line HAART. 6th European HIV Drug Resistance Workshop, 26-28 March 2008.
Geretti AM, Harrison LJ, Green H, Sabin CA, Hill T, Fearnhill E, Pillay D, Dunn DT.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. International HIV Drug Resistance Workshop 2016.
Geretti AM, Phillips AN, Kaye S, Booth C, Mackie N, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2009.  Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viraemia. 18th International HIV Drug Resistance Workshop, June 2009.
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT.  2018.  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.
Geretti AM, Sabin CA, Dunn DT, Nebbia G, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and I214 are associated with drug experience and specific RT mutation patterns. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.